Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/bmt.2017.80 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spatial confinement growth of high-performance persistent luminescence nanoparticles for image-guided sonodynamic therapy.
Acta Biomater
December 2024
State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, PR China; Xiamen Key Laboratory of Rare Earth Photoelectric Functional Materials, Xiamen Institute of Rare Earth Materials, Haixi Institute, Chinese Academy of Sciences, Xiamen 361021, PR China; Fujian Science and Technology Innovation Laboratory for Optoelectronic Information of China, Fuzhou 350108, PR China. Electronic address:
Near-infrared (NIR) persistent luminescence nanoparticles (PLNPs) have significant potential in diagnostic and therapeutic applications owing to their unique persistent luminescence (PersL). However, obtaining high-performance NIR PLNPs remains challenging because of the limitations of current synthesis methods. Herein, we introduce a spatial confinement growth strategy for synthesizing high-performance NIR PLNPs using hollow mesoporous silica (hmSiO).
View Article and Find Full Text PDFPlerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34 + cells in patients with relapsed-refractory diffuse large B-cell lymphomas.
Ann Hematol
December 2024
Hematology and Transplant Unit, "Cardinal Panico" Hospital, Tricase, LE, Italy.
Lymphoma and plasma cell disorders are the most common indications for autologous hematopoietic stem cell (HSC) transplantation. We conducted a prospective multicenter study with the aim of testing the feasibility of plerixafor (PLX) in combination with R-DHAP and G-CSF in 37 patients with relapsed refractory diffuse large B-cell lymphoma (R/R DLBCL) in order to collect a large number of HSC with a goal of transplantation. After R-DHAP, daily monitoring of peripheral blood CD34 + cells by flow cytometry was performed starting on day + 13.
View Article and Find Full Text PDFComparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.
Bone Marrow Transplant
November 2024
Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
In fit patients with newly diagnosed myeloma, high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is considered standard of care. For mobilization of CD34+ cells for ASCT, combined cytotoxic chemotherapy and G-CSF is commonly used. However, the importance of cytostatic chemotherapy for reliable mobilization remains unclear.
View Article and Find Full Text PDFBilateral exudative retinal detachment with subretinal light-chain protein in a patient with multiple myeloma -case report.
BMC Ophthalmol
October 2024
Department of Ophthalmology, University Hospital Schleswig Holstein, Arnold-Heller Str. 3, 24105, Kiel, Germany.
Background: Exudative retinal detachment in patients with multiple myeloma is exceedingly rare. Only two Cases are known to us. We successfully identified light-chain proteins in subretinal fluid, allowing for a more precise understanding of the pathogenesis of this complication.
View Article and Find Full Text PDFOptimal infused CD34 cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
Blood Cancer J
October 2024
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34 cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront transplant between 2005 and 2021 and divided them into low (≤2.5 × 10 cells/kg) and high (>2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!